课题基金 / 基金详情

Human kallikrein subtypes produced by gynecplogical cancer

Human kallikrein subtypes produced by gynecplogical cancer
妇科癌症产生的人激肽释放酶亚型
批准号:
16591678
负责人:
MIYAGI Etsuko
金额:
$1.7万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2007

项目摘要

项目成果

MIYAGI Etsuko的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
【Objectives】 Some kinds of serine proteases are known to play important roles in the process of malignant progression of cancer cells. In addition, prostate specific antigen (PSA) , which is identical to human kallikrein 3, has been an effective biomarker for prostate cancer. However, little is known about the role of kallikrein (KLK) subtypes, which have activities like trypsin and chymotrypsin in the progression of ovarian cancer.【Methods】Gene expression of KLK subtypes 4,5,6,9,10 and 11 were examined quantitatively using RT-PCR methods in both ovarian cancer cell lines and tissues.【Results】 (1) In 9 ovarian cancer cell lines and 28 ovarian cancer tissues, KLK 10 gene was revealed to be expressed frequently(cell lines 89%, tissues 100%) and to a high degree. (2) KLK 5 had a tendency to be expressed highly in serous and endometrioid adenocarcinoma tissues compared to clear and mucinous adenocarcinoma. (3) Clear cell adenocarcinoma showed high degree KLK 6 expression and low degree KLK5, 11. In serous adenocarcinoma tissues, KLK 11 was highly expressed compared to the other tissue types. (4) There was no correlation between the gene expression of KLK subtypes and clinical stages or serum CAl25 levels.【 Conclusions】 It was revealed that ovarian cancer cells express various KLK subtypes. KLK 10 was found to have possibility as a new biomarker of ovarian adenocarcinoma considering very high frequent and high degree gene expression. In addition, various expression patterns of KLK subtypes may relate to specific clinical characteristics in some tissue types of ovarian cancer.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
卵巣癌におけるカリクレインサブタイプの遺伝子発現の検討
卵巢癌中激肽释放酶亚型基因表达的检测
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Morita, A, 宮城 悦子]
通讯作者: 宮城 悦子
Evaluation of gene expression of human kallikrein subtypes in the ovarian cancer cell lines and tissues
卵巢癌细胞系和组织中人激肽释放酶亚型基因表达的评估
DOI: --
发表时间: 2008
期刊:
影响因子: --
作者: [Miyagi, E]
通讯作者: E
Proteomic search for potential diagnostic markers and therapeutis targets for ovarian clear cell adenocarcinoma, 査読, 2006
卵巢透明细胞腺癌潜在诊断标记物和治疗靶标的蛋白质组学搜索,同行评审,2006 年
DOI: --
发表时间: 2006
期刊: Proteomics 6
影响因子: --
作者: [Asato, T., et al., Koizume S, Morita A]
通讯作者: Morita A
Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma.
蛋白质组学寻找卵巢透明细胞腺癌的潜在诊断标记物和治疗靶点。
DOI: --
发表时间: 2006
期刊: Proteomics 6
影响因子: --
作者: [Morita A, Miyagi E, Yasumitsu E, Kawasaki H, Hirano H, Hirahara F]
通讯作者: Hirahara F
Study to overcome the inherent chemoresistance of ovarian clear cell adenocarcinoma based on the functional analyses of ANXA4 molecular subtypes
  • 批准号:
    25462602
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $3.16万
  • 财政年份:
    2013
  • 负责人:
    MIYAGI Etsuko
  • 依托单位:
Elucidating a determinant of development as a novel therapeutic target of ovarian clear cell adenocarcinoma
  • 批准号:
    22591860
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.83万
  • 财政年份:
    2010
  • 负责人:
    MIYAGI Etsuko
  • 依托单位:
海外基金